Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cencora (formerly AmerisourceBergen) is the second-largest pharmaceutical wholesaler in the U.S., distributing branded and generic drugs to pharmacies, hospitals, and physician practices across North America. The company operates a low-margin, high-volume distribution model with ~$321B in revenue, supplemented by higher-margin specialty pharmacy services (oncology, rare diseases) and manufacturer services including patient access programs and data analytics.
Cencora earns thin gross margins (3.2%) on pharmaceutical distribution through per-unit fees negotiated with manufacturers and spread pricing to customers. Operating leverage comes from scale efficiencies across 40+ distribution centers processing 1.5M+ shipments daily. Higher-margin specialty pharmacy (8-12% gross margins) and manufacturer services (15-20% gross margins) provide earnings diversification. The company benefits from generic drug launches (higher initial margins), biosimilar adoption, and long-term pharmaceutical utilization growth driven by aging demographics and chronic disease prevalence. Pricing power is limited due to oligopolistic competition (McKesson, Cardinal Health) and customer consolidation, but switching costs are high given supply chain integration.
Generic drug launch pipeline and timing - new generic introductions drive 200-400bps margin expansion in first 6-12 months before normalization
Specialty pharmacy revenue growth rate - oncology and rare disease distribution growing 8-12% annually with superior margins
Manufacturer fee negotiations and contract renewals - distribution service agreements (DSAs) with top 20 pharma manufacturers represent 60%+ of volume
GLP-1 obesity drug distribution volumes - Wegovy, Ozempic, and competing products represent high-growth, high-margin specialty opportunity
Biosimilar adoption rates in U.S. market - Humira, Stelara, and other biosimilar launches create margin opportunities similar to generics
PBM vertical integration and disintermediation - CVS/Caremark, Cigna/Express Scripts own retail/mail pharmacies and may bypass wholesalers for direct manufacturer relationships, threatening 20-25% of addressable market
Drug pricing reform and margin compression - potential legislation capping Medicare Part D costs, allowing importation, or mandating transparent pricing could reduce manufacturer willingness to pay distribution fees
Amazon Pharmacy expansion - direct-to-consumer fulfillment for maintenance medications could disintermediate retail pharmacy channel representing 40% of volumes
Oligopoly pricing discipline breakdown - McKesson (40% market share) and Cardinal Health (25% share) compete aggressively for large health system contracts, limiting pricing power
Specialty pharmacy competition from payer-owned entities - UnitedHealth/Optum, Cigna/Evernorth building captive specialty pharmacies to capture higher margins, threatening 10-12% revenue segment growing at double-digit rates
High financial leverage (4.15x debt/equity, $15B+ gross debt) limits M&A flexibility and increases refinancing risk if credit markets tighten
Working capital volatility - inventory levels fluctuate $1-2B quarterly based on manufacturer buying opportunities and generic launch timing, creating cash flow variability
Opioid litigation contingent liabilities - $6.1B settlement with states over 18 years creates ongoing cash outflow of $300-400M annually through 2038
low - Pharmaceutical utilization is non-discretionary and driven by demographics rather than GDP. Prescription volumes show minimal correlation to economic cycles. However, specialty drug mix shift accelerates during economic expansions as insurers approve more expensive therapies and patients have better coverage. Generic dispensing rates may increase 1-2% during recessions as cost pressures mount.
Rising rates modestly pressure valuation multiples (stock trades at 20x EV/EBITDA vs. 15x historical average in low-rate environment) but minimal operational impact. Working capital financing costs increase with higher rates - every 100bps rate increase adds ~$40-50M annual interest expense on $10-12B average working capital needs. However, pharmaceutical distribution contracts often include inflation adjusters that partially offset cost increases. The 4.15x debt/equity ratio makes the company more rate-sensitive than healthcare peers.
Moderate exposure to customer credit quality. Independent pharmacy customers (15-20% of revenue) face pressure from PBM reimbursement cuts and may experience higher bad debt during economic stress. Hospital systems (25-30% of revenue) have strong credit profiles. The company maintains tight credit management with 22-25 day DSO. Manufacturer creditworthiness is minimal risk given top-tier pharma company customers.
value - Stock trades at 0.2x P/S (below 0.25x historical average) with 4.7% FCF yield. Attracts investors seeking defensive healthcare exposure with modest growth (5-8% EPS), strong cash generation ($3-4B annual FCF), and capital returns (3-4% buyback yield). The 101% ROE (driven by high leverage) appeals to investors comfortable with financial engineering. Limited dividend (0.8% yield) means total return depends on buybacks and multiple expansion.
low - Beta typically 0.7-0.8. Daily moves rarely exceed 2-3% absent earnings surprises. Stock correlates more with healthcare sector (XLV) than broader market. Volatility spikes occur around generic launch timing misses, PBM contract losses, or drug pricing legislation headlines. The 47.6% one-year return (vs. 24% six-month) reflects multiple expansion as rate cut expectations improved and specialty pharmacy growth accelerated.
